Response rate higher but more adverse events seen at week 12 in patients with plaque psoriasis receiving tapinarof versus vehicle control<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 9, 2021 (HealthDay News) — For adults with plaque psoriasis, tapinarof cream is better than vehicle control for reducing disease severity, according to a study published in the Dec. 9 issue of the New England Journal of Medicine<\/em>.<\/p>\n Mark G. Lebwohl, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted two identical phase 3 randomized trials of tapinarof in adults with mild-to-severe plaque psoriasis. Adults with a baseline Physician’s Global Assessment (PGA) score of 2 (mild) to 4 (severe) and 3 to 20 percent of total body-surface area affected were randomly assigned in a 2:1 ratio to 12 weeks of tapinarof 1 percent cream or vehicle cream once daily. A total of 510 and 515 patients were enrolled in trials 1 and 2, respectively.<\/p>\n The researchers found that a PGA response occurred in 35.4 and 6.0 percent of patients in the tapinarof and placebo groups, respectively, in trial 1 and in 40.2 and 6.3 percent of patients, respectively, in trial 2. For secondary end points and patient-reported outcomes, the results were mainly in the same direction. Folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection, and pruritus were adverse events associated with tapinarof cream.<\/p>\n “In these 12-week trials, the topical aryl hydrocarbon receptor-modulating agent tapinarof was superior to vehicle in reducing the manifestations of psoriasis but was associated with local adverse events and headache,” the authors write.<\/p>\n The study was funded by Dermavant Sciences, the manufacturer of tapinarof.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n